Intracranial epidermoid cysts (IECs) are benign congenital lesions accounting for 0.2%–1.8% of primary intracranial tumours.^{Reference Eatz, Elarjani and Chen1} They commonly occur at the cerebellopontine angle (CPA), presenting with headaches and cranial neuropathies.^{Reference Eatz, Elarjani and Chen1} Herein, we report a case of IEC that underwent malignant transformation into squamous cell carcinoma (SCC) 14 months post-resection. We discuss a novel treatment paradigm with pembrolizumab, carboplatin, capecitabine and radiation therapy. Additionally, we conducted a systematic review of IECs undergoing early malignant transformation.

A 48-year-old healthy female presented with left-sided tinnitus and vertigo. MRI revealed a diffusion-restricted left CPA lesion (Figure 1A). She underwent a left retrosigmoid craniotomy with gross total resection. Pathology was consistent with an IEC. As the surgery was performed at an outside institution, the excised tissue was not available for further pathological or molecular testing. Fourteen months later, she presented again with progressive headache, nausea, vomiting and diplopia. MRI of the brain revealed an enlarging, peripherally enhancing cystic lesion within the prior resection cavity (Figure 1B–C). MRI spine confirmed leptomeningeal dissemination in the lumbar and sacral spine.

Figure 1.

(A) Axial diffusion-weighted imaging (DWI) MRI of the benign-appearing left cerebellopontine angle tumour (43 × 17 mm) with diffusion restriction 11 months prior to index resection. (B) Axial T2 Fluid-attenuated inversion recovery (FLAIR) and (C) coronal T1 contrast-enhanced MRI demonstrating recurrent left cerebellopontine angle tumour (32 × 26 mm) 14 months post-index resection.

She underwent re-operation with fenestration and cyst drainage. A subtotal resection was undertaken as the cyst was adherent to surrounding neurovascular structures. Pathology revealed atypical keratinising squamous cells, dyskeratotic keratinocytes and a brisk mitotic rate. Immunohistochemistry demonstrated strong pan-keratin (AE1/AE3, CAM5.2, Dako Cytokeratin), diffusely positive p40 and focal epithelial membrane antigen (EMA) immunoreactivity; negative p16, SOX10, MelanA and HMB45; Ki67 index 25%–30%; and PD-L1 (clone 22C3) tumour proportion score of 40% (Figure 2). Personalised oncogenomic testing with next-generation DNA sequencing identified homozygous deletions in BARD1, MTAP and CDKN2A/B, FANCA intron 10 mutation, ETV6-CDK6 fusion and TP53 R282P single nucleotide variant. The pathological diagnosis on re-resection was malignant SCC.

Figure 2.

Haematoxylin and eosin (H&E) stains show fragments of atypical keratinising squamous cells infiltrating fibrous tissue with dyskeratotic keratinocytes and elevated mitotic rate consistent with squamous cell carcinoma. Immunohistochemistry demonstrates diffusely positive p40, p16 negative, strong pan-keratin (AE1/AE3, CAM5.2, Dako Cytokeratin), melanA negative, Ki67 tumour nuclear labelling index approximately 25%–30% and PD-L1 (clone 22C3) tumour proportion score of 40%.

Postoperatively, she received adjuvant radiotherapy (26.7 Gy in 10 fractions) to the tumour bed followed by pembrolizumab (2 mg/kg) and carboplatin (area under curve [AUC] 5 mg/(mL·min)) every 3 weeks, completing four cycles. She then continued pembrolizumab alone every 3 weeks for five cycles. During this time, an MRI of the brain revealed a leptomeningeal deposit on the left abducens nerve, which was subsequently treated with focal radiation (22.5 Gy in 5 fractions). Given disease progression, she was switched to capecitabine (1250 mg/m² twice daily for 14 days followed by 7 days off) for 5 cycles. She remains alive 20 months after SCC diagnosis, without radiographic progression.

We conducted a systematic review of MEDLINE, EMBASE and Scopus from inception until December 2023 for cases of malignant transformations of IECs within 2 years of diagnosis. This identified 17 patients (8 females, 9 males) with mean age 56.1 (SD: 13.8) years (Supplementary Table 1). Most IECs (71%) were in the CPA. All underwent initial surgical resection with subtotal resection achieved in 71%. All transformed to SCC in a mean 11.0 (SD: 6.6) months post-resection. Two (12%) had leptomeningeal carcinomatosis. Fourteen (82%) cases underwent a second surgery, with six (35%) receiving adjuvant radiotherapy and/or chemotherapy. The mean survival time was 6.8 (SD: 9.1) months.

Despite IECs being considered benign, approximately 135 cases with malignant transformation have been reported.^{Reference Eatz, Elarjani and Chen1} While the average transformation time is 82.7 months,^{Reference Sakamoto, Akimoto, Tsutsumi, Ken, Ichimasu and Kohno2} we observed an accelerated progression within 14 months. Our review identified only 17 other IEC cases progressing to SCC within 2 years of initial diagnosis. The mechanism underlying accelerated malignant transformation remains unknown. Postulated causes include intrinsic tumour (e.g. high proliferative indices, oncogenic mutations predisposing tumours to rapid malignant progression) and patient factors (e.g. altered or compromised immune systems). These factors, combined with surgical manipulation that may promote inflammation and pro-tumourigenic microenvironments, may accelerate progression.

While we cannot fully account for the accelerated malignant transformation in our case, we hypothesise potential contributors based on our genetic analysis. Intratumoural genetic alterations, particularly TP53 mutation and CDKN2A/B homozygous deletion, which both function as tumour suppressor genes commonly altered in head and neck SCC (HNSCC),^{Reference Deneka, Baca and Serebriiskii3} occurred in our case. Further, MTAP loss, also found in our case, has been associated with several solid tumours.^{Reference Tang, Testa and Kruger4} We suspect that chronic inflammation from residual cystic tissue likely further drove transformation.

Personalised onco-genomics ancillary testing can help guide biology-driven therapeutic management, especially with atypical presentations and those without established treatments. In our case, biomarker analysis identified microsatellite stability and low tumour mutational burden, suggesting limited benefit from PD-1 immune checkpoint inhibitor treatment.^{Reference Goodman, Sokol, Frampton, Lippman and Kurzrock5} Notably, recent KEYNOTE-B10 trial results support pembrolizumab efficacy independent of PD-L1 expression,^{Reference Dzienis, Cundom and Fuentes6} suggesting other mechanisms may underlie response in SCC. MTAP loss suggests potential benefit from anti-metabolite therapies,^{Reference Tang, Testa and Kruger4} with capecitabine selected in our case because of its role in HNSCC treatment and evidence of blood-brain barrier penetrance.^{Reference Morikawa, Peereboom and Thorsheim7–Reference Bachelot, Romieu and Campone9}

Given the rarity of IEC malignant transformation, multidisciplinary collaboration is essential to guide management. In our case, treatment included surgical resection, adjuvant radiation therapy and chemotherapy. Our review found that while all cases underwent surgery, only 35% received adjuvant therapies. Adjuvant radiation therapy has been noted to yield higher overall survival than surgery alone.^{Reference Eatz, Elarjani and Chen1} Currently, there is no standard chemotherapy regimen for primary intracranial SCC. We report novel pembrolizumab and carboplatin use in primary intracranial SCC, supported by clinical trials reporting promising HNSCC antitumour activity and safety.^{Reference Dzienis, Cundom and Fuentes6} Following cycle completion, our patient started capecitabine, which has shown efficacy in HNSCC and central nervous system (CNS) penetration.^{Reference Morikawa, Peereboom and Thorsheim7} While this remains a novel treatment for primary intracranial SCC, our patient has responded positively with no clinical or radiographical progression. Leptomeningeal dissemination from solid tumours is associated with poor prognosis and survival. Our patient received seven cycles of pembrolizumab prior to disease progression and remains alive on next-line therapy, despite leptomeningeal disease, supporting a therapeutic impact of immunotherapy. There is an ongoing phase III trial evaluating cetuximab and palbociclib use for CDKN2A homozygous loss in recurrent and metastatic HNSCC,^{Reference Adkins, Oppelt and Lu10} which may be a future treatment option for our case.

Herein, we describe a case of accelerated progression of IEC to malignant SCC. Following surgical re-resection and radiation therapy, we achieved remarkable tumour stability with the novel application of pembrolizumab, carboplatin and capecitabine. Our review identified 17 other cases of early malignant transformation of IECs with a mean survival time of 6.8 months. Our patient remains alive 20 months following malignant transformation, without radiographic progression, demonstrating the potential benefit of our treatment paradigm. Further research is needed to determine the molecular and genetic factors contributing to accelerated malignant progression of IECs.